Holen Sie sich die Stockscreener-App
5.49
4.56%
0.23
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Altimmune Inc Aktie (ALT) Neueste Nachrichten
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide - Investing.com Australia
Altimmune at Leerink’s Global Healthcare Conference: Strategic Insights on Pemvidutide By Investing.com - Investing.com South Africa
Altimmune, Inc. to Host Earnings Call - ACCESS Newswire
Rhumbline Advisers Has $756,000 Stake in Altimmune, Inc. (NASDAQ:ALT) - Defense World
HC Wainwright Has Bearish Estimate for Altimmune Q2 Earnings - Defense World
Altimmune to Host Virtual R&D Day on March 13, 2025 - The Manila Times
Altimmune, Inc. Announces Virtual R&D Day Focused on Pemvidutide Development and Upcoming Trial Data - Nasdaq
Can Altimmune's Pemvidutide Transform Both Obesity and MASH Treatment? R&D Day to Reveal Full Potential - StockTitan
Altimmune FY2029 EPS Forecast Decreased by HC Wainwright - Defense World
Altimmune, Inc. Class Action: Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
H.C. Wainwright maintains Altimmune stock Buy rating, $12 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Altimmune stock Buy rating, $12 target - Investing.com India
Altimmune (NASDAQ:ALT) Receives “Buy” Rating from HC Wainwright - Defense World
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
(ALT) On The My Stocks Page - Stock Traders Daily
Altimmune Stock: A Deep Dive Into Analyst Perspectives (4 Ratings) - Benzinga
Altimmune to Participate in the Leerink Global Healthcare Conference - The Manila Times
Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
B. Riley Has Optimistic Outlook of Altimmune FY2025 Earnings - Defense World
ALTIMMUNE, INC. (NASDAQ: ALT) INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Altimmune, Inc. - ACCESS Newswire
Levi & Korsinsky Notifies Shareholders of Altimmune, Inc.(ALT) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire
William Blair Begins Coverage on Altimmune (NASDAQ:ALT) - Defense World
Altimmune Inc (ALT) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Rising R&D Costs - GuruFocus.com
William Blair Initiates Coverage of Altimmune (ALT) with Market Perform Recommendation - MSN
Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.83 - MarketBeat
Altimmune, Inc. (NASDAQ:ALT) Q4 2024 Earnings Call Transcript - MSN
Altimmune (NASDAQ:ALT) Releases Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
Altimmune Retail Buzz Heats Up On MASH Progress, FDA Nod For New Trials: Stock Jumps After Q4 Print - NewsBreak
This CoStar Group Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga India
Altimmune Q4 Earnings Review: The Big News Is The MASH With Obesity Data Readout Due In Q2 - Seeking Alpha
William Blair Initiates Coverage of Altimmune (LSE:0A4C) with Market Perform Recommendation - Nasdaq
Investors in Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your RightsALT - ACCESS Newswire
William Blair Initiates Altimmune at Market Perform -February 28, 2025 at 07:51 am EST - Marketscreener.com
Altimmune Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Yahoo Finance
Altimmune, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky for More InformationALT - ACCESS Newswire
Altimmune Reports Progress in Clinical Trials and Financials - TipRanks
Shareholders that lost money on Altimmune, Inc. (ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - ACCESS Newswire
Shareholders that lost money on Altimmune, Inc.(ALT) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Altimmune, Inc. (ALT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Levi & Korsinsky Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 5, 2024ALT - ACCESS Newswire
Altimmune Files For Mixed Shelf Offering Of Up To $400 Million- SEC Filing -February 27, 2025 at 05:34 pm EST - Marketscreener.com
Altimmune reports Q4 EPS (33c), consensus (34c) - TipRanks
Earnings call transcript: Altimmune Q4 2024 sees stock surge 7.41% By Investing.com - Investing.com South Africa
Earnings call transcript: Altimmune Q4 2024 sees stock surge 7.41% - Investing.com
Altimmune Reports 2024 Financial Results and R&D Progress - TipRanks
0.17%
8.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):